Wall Street Zen upgraded shares of Replimune Group (NASDAQ:REPL – Free Report) from a sell rating to a hold rating in a report published on Saturday morning,Wall Street Zen reports.
A number of other equities research analysts have also commented on the company. Leerink Partners increased their price target on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. Wolfe Research upgraded Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. boosted their price objective on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 26th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective on the stock in a research note on Friday, August 7th. Finally, Weiss Ratings cut Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $14.33.
Check Out Our Latest Stock Report on REPL
Replimune Group Stock Up 10.7%
Shares of Replimune Group stock opened at $19.49 on Friday. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00. Replimune Group has a 1-year low of $1.50 and a 1-year high of $19.67. The firm’s 50-day moving average price is $13.67 and its two-hundred day moving average price is $9.40.
Replimune Group (NASDAQ:REPL – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.24. On average, sell-side analysts expect that Replimune Group will post -2.61 EPS for the current year.
Insider Activity at Replimune Group
In other news, CEO Sushil Patel sold 39,341 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $510,252.77. Following the transaction, the chief executive officer directly owned 708,151 shares in the company, valued at approximately $9,184,718.47. This represents a 5.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,467.59. Following the sale, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. This trade represents a 4.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 79,124 shares of company stock valued at $1,038,364 over the last ninety days. Company insiders own 5.40% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of REPL. Mirae Asset Global Investments Co. Ltd. bought a new position in Replimune Group in the third quarter valued at about $64,000. Vise Technologies Inc. acquired a new stake in Replimune Group in the third quarter worth about $163,000. China Universal Asset Management Co. Ltd. raised its holdings in Replimune Group by 30.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company’s stock worth $223,000 after purchasing an additional 4,050 shares during the last quarter. Maxi Investments CY Ltd bought a new stake in Replimune Group during the 3rd quarter worth about $556,000. Finally, Opaleye Management Inc. bought a new stake in Replimune Group during the 2nd quarter worth about $15,332,000. Institutional investors and hedge funds own 92.53% of the company’s stock.
Replimune Group Company Profile
Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.
Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.
Read More
- Five stocks we like better than Replimune Group
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
